Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Galecto Q3 EPS $(0.54) Down From $(0.50) YoY

Galecto (NASDAQ:GLTO) reported quarterly losses of $(0.54) per share. This is a 8 percent decrease over losses of $(0.50) per share from the same period last year.
byBenzinga Newsdesk
November 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Galecto (NASDAQ:GLTO) reported quarterly losses of $(0.54) per share. This is a 8 percent decrease over losses of $(0.50) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Rona Therapeutics Announced Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

By Charles Gross
July 25, 5:14 AM
Rona Therapeutics, Inc ("Rona"), a fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, today announced that it has obtained worldwide exclusive rights to Sanofi's siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.

SNY